USP Guidelines for Extractables and Leachables Testing

USP Guidelines for Extractables & Leachables Testing | USP 1663 & 1664 Explained Understanding USP Extractables & Leachables (E&L) testing is critical for ensuring the safety of pharmaceutical packaging, container closure systems, and drug delivery devices. In this video, we break down USP 1663 and USP 1664 guidelines, their differences, workflow, and regulatory expectations. USP 1663 focuses on extractables — potential compounds released under exaggerated laboratory conditions, while USP 1664 evaluates leachables — compounds that actually migrate into the drug product during real storage and use conditions. These studies are essential for patient safety, regulatory approval, and lifecycle risk management. Read the full article here: https://resolvemass.ca/usp-extractables-and-leachables/ If you work in pharmaceuticals, medical devices, biologics, or regulatory affairs, this video will help you understand how USP E&L guidelines impact product development and approval. 👍 Like | 💬 Comment | 🔔 Subscribe for more pharma regulatory content #USP1663 #USP1664 #ExtractablesAndLeachables #USPguidelines #ELtesting #PharmaceuticalAnalysis #ContainerClosure #DrugPackaging #RegulatoryAffairs #PharmaDevelopment #AnalyticalChemistry #GCMS #LCMS #ICPMS #MedicalDevices #CombinationProducts #PharmaQuality #DrugSafety #ICHQ3E #ToxicologicalRiskAssessment #PharmaYouTube #PharmaEducation #PharmaTraining #BioPharma #PharmaIndustry #ANDA #NDA #PharmaRegulatory